Sophia Abene

This week, a measles outbreak spans multiple US states and the CDC highlights a rise in syphilis incidents. Fatalities from Group A strep infections have doubled since last year in Canada, and people who inject drugs are at higher risk for hepatitis C and HIV. Investigators are also tracking incident rates over time post-COVID-19 pandemic.

Study shows both recent and earlier use of these medications significantly heightens the risk.

Group A streptococcal infections outbreak nearly doubles fatalities from the previous year.

CDC's preventive strategies against the world's most prevalent mosquito-borne disease.

A new study reveals that the cholera vaccine's diminished efficacy highlights the need for improved strategies in combating a global health challenge.

Study examines the complexity between human health and tick-borne diseases.

This week CDC discusses vaccine recommendations; a provider offers insights on administering live biotherapeutics; and early administration of simnotrelvir plus ritonavir shortened the time to sustained resolution of COVID-19 symptoms.

New challenges in the fight against gonorrhea in the US.

UCLA-led study examines outcomes in infants born to mothers exposed to SARS-CoV-2 during pregnancy.

The CDC stresses the importance of hepatitis B virus (HBV) vaccination, but challenges in treatment accessibility persist.

Early administration of simnotrelvir plus ritonavir shortened the time to sustained resolution of COVID-19 symptoms.

New study reinforces the importance of early detection and vaccination against bacterial meningitis.

Changes encompass clarification of recommendations for scheduled vaccinations and the addition of the RSV vaccines for the first time.

With it comes the possibility for international cooperation regarding an investigational Middle East Respiratory Syndrome (MERS) vaccine.

Investigators uncover a convergent evolution of enhanced innate immune antagonist expression associated.

Here are some insights into the comparative analysis of COVID and non-COVID pneumonia.

Pfizer’s vaccine protection waned from the former variant to the latter but still afforded a high efficacy for these patient populations.

A new human trial aims to prevent the fatal, zoonotic-borne disease.

A new study warns an increase in costs could lead to new infections.